| Identification | More | [Name]
H-LYS(Z)-OME HCL | [CAS]
27894-50-4 | [Synonyms]
H-LYS(Z)-OME HCL
H-LYS(Z)-OME HYDROCHLORIDE
L-LYSINE(CBZ) METHYL ESTER HCL
L-LYSINE-CBZ-METHYL ESTER HYDROCHLORIDE
LYSINE(Z)-OME HCL
N-EPSILON-BENZYLOXYCARBONYL-L-LYSINE METHYL ESTER HYDROCHLORIDE SALT
N-EPSILON-CARBOBENZOXY-L-LYSINE METHYL ESTER HYDROCHLORIDE
N(EPSILON)-CBZ-L-LYSINE METHYL ESTER HYDROCHLORIDE
N-EPSILON-CBZ-L-LYS METHYL ESTER HCL
N-EPSILON-Z-L-LYSINE METHYL ESTER HYDROCHLORIDE
H-Lys(Z)-OMe.HCI
Nε-Z-L-lysine methyl ester hydrochloride
methyl N6-benzyloxycarbonyl-L-lysinate hydrochloride
N(epsilon)-Benzyloxycarbonyl-L-lysine methyl ester hydrochloride
N-E-Z-L-lysine methyl ester hydrochloride
N-Benzyloxycarbonyl-L-lysine methyl ester hydrochloride
Lys(Z)-OMe HCl
N-ε-Z-L-lysine methyl ester hydrochloride
N-E-CBZ-L-LYSINE METHYL ESTER HCL
H-LYS(Z)-OME.HCL 99+% | [EINECS(EC#)]
248-715-9 | [Molecular Formula]
C15H23ClN2O4 | [MDL Number]
MFCD00034846 | [Molecular Weight]
330.81 | [MOL File]
27894-50-4.mol |
| Chemical Properties | Back Directory | [Melting point ]
115-118°C | [storage temp. ]
−20°C
| [solubility ]
Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | [form ]
Powder | [color ]
White to off-white | [Optical Rotation]
[α]20/D +14.5±0.5°, c = 2% in H2O | [BRN ]
3578476 | [Major Application]
peptide synthesis | [InChI]
1S/C15H22N2O4.ClH/c1-20-14(18)13(16)9-5-6-10-17-15(19)21-11-12-7-3-2-4-8-12;/h2-4,7-8,13H,5-6,9-11,16H2,1H3,(H,17,19);1H/t13-;/m0./s1 | [InChIKey]
QPNJISLOYQGQTI-ZOWNYOTGSA-N | [SMILES]
Cl.COC(=O)[C@@H](N)CCCCNC(=O)OCc1ccccc1 | [CAS DataBase Reference]
27894-50-4(CAS DataBase Reference) |
| Safety Data | Back Directory | [Safety Statements ]
S22:Do not breathe dust .
S24/25:Avoid contact with skin and eyes . | [WGK Germany ]
3
| [HS Code ]
2924297099 | [Storage Class]
11 - Combustible Solids |
| Hazard Information | Back Directory | [Chemical Properties]
White powder | [Uses]
H-Lys(Z)-OMe Hydrochloride is a reagent in the development of human calcitonin gene-related peptide (CGRP) receptor antagonists for treatment of acute migraine. | [reaction suitability]
reaction type: solution phase peptide synthesis |
|
|